← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $611B	3,625	-49	-1%	$296B
2	2 Pfizer PFE $169B	3,088	-72	-2%	$170B
3	3 Merck MRK $363B	2,992	-23	-0.8%	$163B
4	4 AbbVie ABBV $503B	2,971	-35	-1%	$164B
5	5 Bristol-Myers Squibb BMY $124B	2,472	-68	-3%	$116B
6	6 Amgen AMGN $238B	2,324	-29	-1%	$92.5B
7	7 Gilead Sciences GILD $197B	1,604	0	0%	$62.2B
8	8 Novartis NVS $287B	1,088	-53	-5%	$13.7B
9	9 Regeneron Pharmaceuticals REGN $82.4B	1,080	+16	+2%	$64B
10	10 AstraZeneca AZN $260B	966	-50	-5%	$28.3B
11	11 GSK GSK $98.6B	742	-159	-18%	$7.87B
12	SGEN 12 DELISTED Seagen Inc. Common Stock SGEN	539	-9	-2%	$22.2B
13	13 Incyte INCY $23B	537	0	0%	$14.2B
14	14 DELISTED Exact Sciences EXAS	480	-21	-4%	$5.26B
15	15 Jazz Pharmaceuticals JAZZ $13.9B	468	0	0%	$7.59B
16	16 Exelixis EXEL $15.5B	400	+25	+7%	$4.33B
17	17 Halozyme HALO $13.8B	356	-12	-3%	$5.21B
18	18 Lantheus LNTH $6.53B	352	+31	+10%	$4.74B
19	19 Guardant Health GH $22.4B	328	-4	-1%	$5.04B
20	20 Qiagen QGEN $9.57B	296	+8	+3%	$5.73B
21	21 Natera NTRA $58.3B	287	+28	+11%	$4.11B
22	22 Takeda Pharmaceutical TAK $62.6B	276	-7	-2%	$829M
23	23 BioNTech BNTX $22.7B	264	-28	-10%	$5.01B
24	24 NeoGenomics NEO $2.2B	245	+6	+3%	$969M
25	25 Iovance Biotherapeutics IOVA $6.51B	242	+5	+2%	$1.48B